Biotech RadarJobs updated

COMPANY

Amgen

HQ: Thousand Oaks, CA source · amgen.com ↗ · West Coast

FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3

1,746 open jobs · last seen Oct 22, 2026 · 58 sources

Keywords: oncology metabolic rare disease heart disease obesity rare diseases Overweight Extensive Stage Small Cell Lung Cancer Type 2 Diabetes Mellitus Obstructive Sleep Apnea Small Cell Lung Cancer Atherosclerotic Cardiovascular Disease Obesity or Overweight Cardiometabolic Disease Active Juvenile Psoriatic Arthritis Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Systemic Lupus Erythematosus Active Refractory Rheumatoid Arthritis Generalized Myasthenia Gravis Plaque Psoriasis Membranous Glomerulonephritis Antineutrophil Cytoplasmic Antibody-associated Vasculitis Neovascular Age-related Macular Degeneration nAMD Overweight or Obesity and Elevated Liver Fat Non-Small Cell Lung Cancer Ewing Sarcoma Metastatic Castration-resistant Prostate Cancer Relapsing-remitting Multiple Sclerosis Migraine Coronary Artery Disease Hypercholesterolemia Atheroma Atherosclerotic Plaque Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) Gout Primary Immune Thrombocytopenia Heart Failure With Preserved Ejection Fraction Heart Failure With Mildly Reduced Ejection Fraction Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia Sjogren's Syndrome End-Stage Renal Disease Psoriatic Arthritis

Location: Thousand Oaks, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

1,746+1 patient-care hiddenOpen jobs1,043Trials (company is sponsor)10FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
オンコロジー事業本部　固形がん領域MRJapan - TokyoOct 22, 2026Oct 9, 2026
Order-to-Cash Product ExecutionIndia - HyderabadOct 22, 2026Oct 9, 2026
Associate Director, Biomedical Data Stewardship (Standards Lead)India - HyderabadOct 22, 2026Oct 9, 2026
Sr. Data Scientist – AI Driven Operations ResearchIndia - HyderabadOct 22, 2026Oct 9, 2026
Maintenance ManagerIreland - DublinOct 22, 2026Oct 16, 2026

See all 1,746 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Trial start Phase 3: A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia source ↗
  2. Trial start Phase 4: A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma source ↗
  3. Trial start Phase 3: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes source ↗
  4. Trial start —: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy source ↗
  5. Trial start Phase 1: Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose source ↗
  6. Board tracked Radar started tracking this company’s job board (1,747 open jobs at last check). source ↗
  7. Trial start 3: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy source ↗
  8. Trial start Phase 1: Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections source ↗
  9. Trial start 3: Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) source ↗
  10. Trial start Phase 3: A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) source ↗
  11. Trial start Phase 3: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) source ↗
  12. Trial start Phase 3: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) source ↗
  13. Trial start Phase 2: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) source ↗
  14. Trial start Phase 3: A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration source ↗
  15. Trial start Phase 3: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) source ↗
  16. Trial start Phase 1: Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer source ↗
  17. Trial start Phase 1: Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. source ↗
  18. Trial start Phase 1: Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) source ↗
  19. Trial start Phase 1: AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors source ↗
  20. Trial start Phase 2: A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight source ↗
  21. Trial start Phase 3: A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrex source ↗
  22. Trial start Phase 3: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy source ↗
  23. Trial start Phase 1/Phase 2: A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia source ↗
  24. Trial start Phase 3: A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer source ↗
  25. Trial start Phase 3: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy source ↗

Showing 25 of 60 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 1,746

1 patient-care job hidden (phlebotomy, plasma-center, nursing and similar care roles; 1,747 open jobs in total).

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
オンコロジー事業本部　固形がん領域MRJapan - TokyoOct 22, 2026Oct 9, 2026Mid
Order-to-Cash Product ExecutionIndia - HyderabadOct 22, 2026Oct 9, 2026Not stated
Associate Director, Biomedical Data Stewardship (Standards Lead)India - HyderabadOct 22, 2026Oct 9, 2026Senior
Sr. Data Scientist – AI Driven Operations ResearchIndia - HyderabadOct 22, 2026Oct 9, 2026Senior
Maintenance ManagerIreland - DublinOct 22, 2026Oct 16, 2026Not stated
Senior Data Scientist – Perturbation Biology & AIIndia - HyderabadOct 22, 2026Oct 22, 2026Not stated
Biopharmaceutical Representative-CardiologyBulgaria - SofiaOct 22, 2026Oct 22, 2026Not stated
Specialist HR Systems & Solutions- Payroll ConfigurationIndia - HyderabadOct 22, 2026Oct 22, 2026Not stated
Sr. Associate - Technology Project ControllerIndia - HyderabadOct 22, 2026Oct 22, 2026Not stated
Associate Software EngineerIndia - HyderabadOct 22, 2026Oct 22, 2026Not stated
Specialist Quality Assurance (Technical Support)Singapore Manufacturing - TuasOct 22, 2026Oct 22, 2026Not stated
Sr Biopharmaceutical Rep-Repatha-ZhengzhouChina - ZhengzhouOct 22, 2026Oct 22, 2026Not stated
Commercial Forecasting Senior AssociatePortugal - LisbonOct 21, 2026Oct 9, 2026Mid
Process Development Associate ScientistUS - California - Thousand OaksOct 21, 2026Oct 9, 2026Mid
Mgr, Maintenance IUS - North Carolina - Holly SpringsOct 21, 2026Oct 9, 2026Not stated
Orchestration Engine, Associate Director2 locations, including Thousand Oaks, California, USOct 21, 2026Oct 9, 2026Senior
Area Network Marketing ManagerJapan - TokyoOct 21, 2026Oct 9, 2026Mid
Director, Scientific and Operations Intelligence, ObesityUS - California - Thousand OaksOct 21, 2026Oct 9, 2026Senior
Executive Director, Research OncologyUS - California - South San FranciscoOct 21, 2026Oct 9, 2026Executive
Manufacturing AssociateUS - California - Thousand OaksOct 21, 2026Oct 22, 2026Not stated
EH&S Sr MgrUS - California - Thousand OaksOct 21, 2026Oct 22, 2026Not stated
Associate Manufacturing - DaysUS - Rhode Island - West GreenwichOct 21, 2026Oct 22, 2026Not stated
Process Development Associate ScientistUS - Massachusetts - CambridgeOct 21, 2026Oct 22, 2026Not stated
Mfg Process Technician - DaysUS - Rhode Island - West GreenwichOct 21, 2026Oct 22, 2026Not stated
Associate Manufacturing-NightsUS - Rhode Island - West GreenwichOct 21, 2026Oct 22, 2026Not stated
Scientist – Inflammation ResearchUS - California - Thousand OaksOct 21, 2026Oct 22, 2026Not stated
Digital Engagement ManagerNetherlands - BredaOct 21, 2026Oct 22, 2026Not stated
EH&S Manager - Risk ManagementUS - North Carolina - Holly SpringsOct 21, 2026Oct 22, 2026Not stated
Patient Access & Reimbursement Marketing Manager,- BiosimilarUS - California - Thousand OaksOct 21, 2026Oct 22, 2026Not stated
International Tax ManagerIreland - DublinOct 21, 2026Oct 22, 2026Not stated
Manufacturing Training Specialist – Manufacturing SupportUS - North Carolina - Holly SpringsOct 21, 2026Oct 22, 2026Not stated
Amgen Graduate Opportunities 2027Ireland - Dun LaoghaireOct 21, 2026Oct 22, 2026Not stated
Learning and Performance Senior Manager - Rest of WorldPortugal - LisbonOct 21, 2026Oct 22, 2026Not stated
Product Specialist Oncology - Veneto OrientaleItaly - MilanOct 21, 2026Oct 22, 2026Not stated
Sr Biopharmaceutical Rep-TongliaoChina - TongliaoOct 21, 2026Oct 22, 2026Not stated
Brand Engagement Manager, CardiovascularJapan - TokyoOct 21, 2026Oct 22, 2026Not stated
Senior Process Engineer - CIP/SIP/AutoclavesUS - North Carolina - Holly SpringsOct 20, 2026Oct 9, 2026Senior
Global Value & Access Senior Manager (Flexible Location: Argentina, Brazil, Colombia, Mexico City)4 locations, including Bogota, ColombiaOct 20, 2026Oct 9, 2026Senior
SIEM EngineerPortugal - LisbonOct 20, 2026Oct 9, 2026Mid
Senior Director, Consumer Pricing & Non-Reimbursed Channels, Obesity and Related Conditions (OaR)United States - RemoteOct 20, 2026Oct 9, 2026Senior
Senior Maintenance Technician – Utilities (Waste Water Treatment) – Day ShiftUS - North Carolina - Holly SpringsOct 20, 2026Oct 9, 2026Senior
Clinical Development Medical Director, Early Development OncologyUnited States - RemoteOct 20, 2026Oct 9, 2026Senior
Associate ParalegalUS - California - Thousand OaksOct 20, 2026Oct 9, 2026Mid
Specialty/Senior Specialty Representative - Cardiovascular - Springfield, IlUS - Missouri - St. LouisOct 20, 2026Oct 16, 2026Not stated
Sr. Medical Science Liaison - Obesity and Related Conditions - Camden, NJUS - New Jersey - CamdenOct 20, 2026Oct 19, 2026Not stated
Scientist, Integrated Computational and Experimental Inflammation DiscoveryUS - California - South San FranciscoOct 20, 2026Oct 22, 2026Not stated
Specialty/Senior Specialty Representative - Cardiovascular - Springfield, IlUS - Illinois - SpringfieldOct 20, 2026Oct 22, 2026Not stated
Administrative Coordinator – CV Cardio-Metabolic and Bone TAUnited States - RemoteOct 20, 2026Oct 22, 2026Not stated
Process Development Senior AssociateUS - California - Thousand OaksOct 20, 2026Oct 22, 2026Not stated
Manager, Value & Access Analytics - GTN Forensics - U.S. RemoteUnited States - RemoteOct 20, 2026Oct 22, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 1,746 jobs →

Clinical trials (lead sponsor) Showing 50 of 1,043

RecordTitlePhaseStatusStartPrimary completion
NCT07037433Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityPhase 3RecruitingJul 25, 2025Jun 30, 2028 (estimated)
NCT07575399Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)Phase 3RecruitingMay 11, 2026Jan 3, 2028 (estimated)
NCT07866066Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesPhase 3Not yet recruitingNov 2, 2026Sep 4, 2028 (estimated)
NCT06585462Single and Multiple Ascending Dose Study of AMG 513 in Participants With ObesityPhase 1CompletedSep 9, 2024Sep 16, 2026 (actual)
NCT07225686Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyPhase 3Active, not recruitingDec 19, 2025Aug 20, 2027 (estimated)
NCT06745323A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC2Active, not recruitingFeb 26, 2025Aug 10, 2029 (estimated)
NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)Phase 3RecruitingJul 23, 2026Dec 26, 2027 (estimated)
NCT04804553Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisPhase 3RecruitingMar 17, 2022Mar 21, 2028 (estimated)
NCT07134088A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic LeukemiaPhase 1/Phase 2Active, not recruitingDec 8, 2025Mar 6, 2031 (estimated)
NCT07811999Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC InjectionsPhase 1RecruitingSep 22, 2026Jan 14, 2027 (estimated)
NCT06570798A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases2RecruitingJul 16, 2025Aug 6, 2028 (estimated)
NCT07684144Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)Phase 3RecruitingJul 29, 2026Dec 26, 2027 (estimated)
NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Phase 2RecruitingJul 21, 2026Mar 13, 2030 (estimated)
NCT07545226Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.Phase 1CompletedApr 21, 2026Sep 2, 2026 (actual)
NCT05565560A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisPhase 3CompletedJan 25, 2023Nov 20, 2025 (actual)
NCT07851220A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy3RecruitingOct 1, 2026Sep 27, 2031 (estimated)
NCT06072482A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisPhase 4RecruitingFeb 7, 2024Dec 31, 2036 (estimated)
NCT07226765Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyPhase 3Active, not recruitingNov 25, 2025Aug 30, 2027 (estimated)
NCT07614776A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationPhase 3RecruitingMay 27, 2026Jul 31, 2027 (estimated)
NCT07441252A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightPhase 2Active, not recruitingMar 5, 2026Aug 25, 2027 (estimated)
NCT05920356A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)Phase 3RecruitingNov 16, 2023Jun 30, 2027 (estimated)
NCT07037758A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)Phase 1RecruitingSep 16, 2025Mar 18, 2028 (estimated)
NCT07297979Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)Phase 1RecruitingApr 8, 2026May 26, 2030 (estimated)
NCT07229157Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityPhase 1CompletedOct 22, 2025Aug 27, 2026 (actual)
NCT07213674A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPhase 3RecruitingNov 28, 2025Jan 7, 2030 (estimated)
NCT06700343Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Phase 3Active, not recruitingJan 13, 2025Apr 19, 2027 (estimated)
NCT07832799Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous DosePhase 1Not yet recruitingOct 12, 2026Mar 23, 2027 (estimated)
NCT03836040Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigrainePhase 3Active, not recruitingJul 19, 2019Nov 19, 2025 (actual)
NCT07803679A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical AtheromaPhase 4Not yet recruitingJan 31, 2027Apr 30, 2029 (estimated)
NCT07403721AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsPhase 1RecruitingApr 8, 2026Jan 1, 2030 (estimated)
NCT07778316Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)3RecruitingAug 28, 2026Sep 24, 2027 (estimated)
NCT06229145A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory GoutPhase 4CompletedMar 18, 2024Jul 30, 2025 (actual)
NCT06858839Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightPhase 3Active, not recruitingMar 12, 2025Jan 21, 2027 (estimated)
NCT07700238A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)Phase 3RecruitingAug 21, 2026Sep 14, 2029 (estimated)
NCT07037459Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPhase 3RecruitingJun 25, 2025Jun 30, 2028 (estimated)
NCT07493512Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerPhase 1RecruitingApr 28, 2026Jul 30, 2030 (estimated)
NCT07223190A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic LeukaemiaPhase 3Not yet recruitingJun 30, 2028Dec 30, 2031 (estimated)
NCT06590051AMG 335 Expanded Access Program for IgG4-Related DiseaseNot listedApproved for marketingNot listedNot listed
NCT06104124A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityPhase 3CompletedJan 24, 2024Jul 23, 2026 (actual)
NCT06468826A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)Phase 1CompletedJun 18, 2024Oct 5, 2024 (actual)
NCT03747939Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.Phase 4CompletedDec 31, 2018Dec 19, 2022 (actual)
NCT06660173A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Phase 2Active, not recruitingNov 7, 2024Oct 6, 2025 (actual)
NCT05111626Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.Phase 3TerminatedMar 14, 2022Oct 14, 2025 (actual)
NCT05361395First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)Phase 1Active, not recruitingAug 24, 2022May 30, 2030 (estimated)
NCT07005128A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Phase 3Active, not recruitingAug 18, 2025Jan 4, 2029 (estimated)
NCT06555796Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerPhase 1Active, not recruitingSep 23, 2024Mar 13, 2027 (estimated)
NCT06295679A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular DiseaseNot listedActive, not recruitingDec 19, 2022Dec 19, 2028 (estimated)
NCT07388498A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled GoutPhase 3RecruitingFeb 9, 2026Jun 18, 2028 (estimated)
NCT06252649Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationPhase 3RecruitingJul 17, 2024Sep 25, 2028 (estimated)
NCT05909761Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyNot listedRecruitingOct 15, 2026Oct 31, 2032 (estimated)

FDA records (last 2 years)

Connect

See your connections at Amgen on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback